Dr. Maja Zorman

Dr. Maja Zorman is a Rheumatologist practising at the University Medical Centre Ljubljana (UKC Ljubljana), Slovenia's foremost academic hospital. With over 14 years of clinical experience in rheumatology, Dr. Zorman delivers specialist care for patients with inflammatory, autoimmune, and musculoskeletal diseases. Her practice is embedded within the Rheumatology Division at UKC Ljubljana, which is affiliated with the University of Ljubljana Faculty of Medicine and serves as Slovenia's national reference centre for complex rheumatological conditions. Dr. Zorman takes a comprehensive approach to rheumatological care, integrating clinical assessment, serological and imaging investigations, and multidisciplinary coordination to achieve accurate diagnosis and effective disease management. She is involved in clinical research on the outcomes of biologic and targeted therapies in Slovenian patients with rheumatoid arthritis and connective tissue diseases, and actively participates in the Slovenian Rheumatological Society.

Dr. Maja Zorman completed her MD from the University of Ljubljana Faculty of Medicine before undertaking specialist residency training in internal medicine and rheumatology at UKC Ljubljana. She earned her PhD through research on the pathogenesis and treatment outcomes of systemic connective tissue diseases in the Slovenian population. Dr. Zorman supplemented her clinical training with fellowship attachments at rheumatology centres in Austria and the Netherlands, gaining exposure to advanced biologic therapy protocols and musculoskeletal ultrasound techniques. She is a member of the Slovenian Rheumatological Society and participates in the EULAR (European League Against Rheumatism) congress and educational programme annually. Her ongoing research contributes to national registries monitoring biologic therapy outcomes in Slovenian rheumatology patients.

Dr. Zorman's rheumatological expertise encompasses inflammatory joint diseases and systemic connective tissue disorders. In inflammatory arthritis, she diagnoses and manages rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and reactive arthritis, using both conventional DMARDs and biologic agents. In connective tissue disease, she manages systemic lupus erythematosus, systemic sclerosis, inflammatory myopathies, mixed connective tissue disease, and primary and secondary Sjögren's syndrome. She has particular expertise in the use of musculoskeletal ultrasound for joint assessment and procedure guidance. Her experience with biologic and targeted synthetic DMARDs includes TNF inhibitors, IL-6 inhibitors, IL-17 inhibitors, abatacept, rituximab, and JAK inhibitors. Dr. Zorman also manages osteoporosis and metabolic bone disease, often as a complication of long-term steroid use in her rheumatological patient population.

Dr. Maja Zorman consults in Slovenian, Croatian, and English, enabling her to serve patients from neighbouring Croatia, as well as the broader international English-speaking community. UKC Ljubljana is Slovenia's national referral hospital and is positioned to receive patients from across the former Yugoslav region and Western Europe. Rheumatology services in Ljubljana are cost-effective relative to Western European centres while adhering to EU and EULAR clinical guideline standards. International patients seeking rheumatology consultations should bring laboratory results including ANA, anti-dsDNA, ANCA, RF, anti-CCP, ESR, CRP, and complement levels; imaging studies including X-rays, MRI and ultrasound; and details of current medications including any biologics.

Dr. Maja Zorman has received recognition from the Slovenian Rheumatological Society for her clinical contributions and research in connective tissue diseases. Her PhD research on systemic rheumatological conditions was commended by the University of Ljubljana Faculty of Medicine. She has presented research at Slovenian and EULAR-affiliated European rheumatology congresses, receiving acknowledgment for her work on biologic therapy outcomes in Slovenian patient populations.